Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 151 Dose Effect in Type 2 Diabetes
NCT01464437Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of arry-403 in type 2 diabetes mellitus (T2DM), sponsored by Amgen. Started Sep 2011; status: completed.
02
Drugs
arry-403
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01464437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01464437.